No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Helus Pharma Inc. (HELP) stock was $10.93 as of Oct 6, 2026, 12:25 PM EDT, down 4.33% from the previous close.
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
Medical - Pharmaceuticals · Toronto, ON
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.67
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.26
vs Estimate
$-1.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HELP | $677.18M | $10.93 | -4.33% | N/A | N/A | N/A | N/A |
| 2ANNX | $678.13M | $4.14 | -1.45% | +31.49% | -26.29% | N/A | vs HELP |
| 3FDMT | $670.70M | $12.83 | -0.70% | +50.81% | -13.08% | N/A | vs HELP |
| 4MDXG | $669.77M | $4.59 | +0.99% | -36.75% | -4.94% | -6.46% | vs HELP |
| 5SLDB | $684.72M | $6.96 | -1.49% | +19.56% | -27.50% | N/A | vs HELP |
| 6AVR | $690.35M | $7.10 | -5.96% | +74.71% | N/A | N/A | vs HELP |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$39.87
+264.9% upside
Low
$14.88
Current
$10.93
High
$68.25
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.70 | $-0.70 | $-0.70 | 3 |
| Quarter ending Dec 2026 | $-0.61 | $-0.61 | $-0.61 | 3 |
| Quarter ending Mar 2027 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Quarter ending Jun 2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-2.96 | $-2.67 | $-2.51 | 4 |
| FY 2028 | $-4.99 | $-2.23 | $-0.52 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $12.98M | $31.70M | $61.88M | 4 |
| FY 2028 | $3.83M | $9.34M | $18.23M | 4 |
